Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Chung-Feng Huang¹²³, Pey-Fang Wu¹⁴, Ming-Lun Yeh¹², Ching-I Huanga, Po-Cheng Liang¹, Cheng-Ting Hsua, Po-Yao Hsu¹, Hung-Yin Luia, Ying-Chou Huanga, Zu-Yau Lin¹², Shinn-Cherng Chen¹², Jee-Fu Huanga¹², Chia-Yen Daia,²,³, Wan-Long Chuanga,² and Ming-Lung Yu¹²,⁵,⁶

¹Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung; ²Faculty of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung; ³Department of Occupational Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung; ⁴Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung; ⁵Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung; ⁶College of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan

Copyright © 2021 by Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

An estimated 71 million subjects are infected with hepatitis C virus (HCV) globally. In addition, approximately 400,000 subjects die from chronic hepatitis C (CHC)-related liver cirrhosis and hepatocellular carcinoma (HCC) each year. HCV infection has been rampant in Taiwan with the seroprevalence of anti-HCV antibodies ranging from 3.3% to 8.6%. A recent survey in first-time blood donors noted that the age-standardized prevalence of anti-HCV antibodies decreased from 27.7 to 9.2 per 1,000 persons in the past two decades, and the age-standardized HCV viremic rate decreased from 5.8 to 3.9 per 1,000 donors between 2013 and 2017. The World Health Organization has set several goals for controlling viral hepatitis by 2030. Nevertheless, the majority of countries are currently off track in meeting these goals. The efficacy of the antiviral treatment for CHC is no longer an obstacle for HCV care due to the important invention of direct-acting antivirals (DAAs). Beyond ensuring blood safety and harm reduction, a thorough HCV care cascade involves proper screening of patients who are unaware of their HCV status, accurate and efficient diagnosis, and linking patients to medical care. Each of these steps is a critical hurdle that adds complexity, which prevents the healthcare system from eliminating HCV infection.

Background/Aims: Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and a late call-back strategy (R.N.A. model) was applied. We aimed to compare the HCV treatment rate of patients treated with this strategy compared to those without.

Methods: One hundred and twenty-five anti-HCV seropositive patients who adopted the R.N.A. model in 2020 and another 1,396 controls treated in 2019 were enrolled to compare the gaps in accurate HCV RNA diagnosis to final treatment allocation.

Results: The HCV RNA testing rate was significantly higher in patients who received reflex testing than in those without reflex testing (100% vs. 84.8%, P<0.001). When patients were stratified according to the referring outpatient department, a significant improvement in the HCV RNA testing rate was particularly noted in patients from non-hepatology departments (100% vs. 23.3%, P<0.001). The treatment rate in HCV RNA seropositive patients was 83% (83/100) after the adoption of the R.N.A. model, among whom 96.1% and 73.9% of patients were from the hepatology and non-hepatology departments, respectively. Compared to subjects without R.N.A. model application, a significant improvement in the treatment rate was observed for patients from non-hepatology departments (73.9% vs. 27.8%, P=0.001). The application of the R.N.A. model significantly increased the in-hospital HCV treatment uptake from 6.4% to 73.9% for patients from non-hepatology departments (P<0.001).

Conclusions: The care cascade increased the treatment uptake and set up a model for enhancing in-hospital HCV elimination. (Clin Mol Hepatol 2021;27:136-143)

Keywords: HCV; Reflex testing; Care cascade; Elimination

Study Highlights

The in-hospital hepatitis C care cascade (R.N.A. model) includes serial modalities: 1) HCV reflex testing (increasing timely and accurate diagnosis), 2) Real-time automatic appointments (enhancing accessibility), and 3) Late call-back for the missing patients (raising awareness). By implementing the model, HCV RNA diagnostic rate improves from 23.3% to 100%, and HCV treatment rate increased from 27.8% to 73.9% in non-hepatology departments.
tient to return for follow-up testing before treatment allocation. Although HCV reflex testing has been consistently applied, this strategy has rarely been executed in Taiwan. Moreover, the suboptimal in-hospital referral of viremic patients to liver clinics may also lead to inferior accessibility and poor treatment uptake. We herein made an effort to identify viremic patients by HCV reflex testing and to preemptively transfer them for in-hospital HCV care by using a real-time appointment and late call-back system. To determine the potential improvement due to the scale-up strategies, the treatment gap was compared to that of another anti-HCV seropositive patient cohort without the abovementioned intervention in terms of the HCV RNA diagnostic rate and treatment rate.

**PATIENTS AND METHODS**

**Patient enrollment**

The order of anti-HCV testing was performed at the clinicians’ discretion depending on the clinical demands. Patients who were newly diagnosed with anti-HCV antibody seropositivity were consecutively enrolled during two time periods in the outpatient departments of a medical center in Taiwan. An in-hospital HCV treatment strategy to scale up the HCV care cascade that included three steps was adopted in December 2019. The first modality involved the use of HCV reflex testing for patients who were anti-HCV seropositive. The testing was initiated by the hospital, and all the medical staff were well informed of the policy via email, text, and conferences before the strategy was executed.

Moreover, an automatic real-time appointment system for the liver clinic was created for patients who were confirmed to have HCV viremia by reflex testing; viremic patients who never visited the liver clinic were referred to the hepatology department immediately for further HCV care regardless of the outpatient department they were visiting at the same time. Finally, a late call back was made by well-trained nursing coordinators for patients from the checklist who missed the appointment (HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system, R.N.A. model) (Fig. 1). Subjects who did not receive the

**Figure 1.** Average number of visits needed to confirm HCV viremia and genotyping for patients with or without HCV reflex testing, and the care cascade of the R.N.A. model. The average of 2.8 visits for traditional testing was calculated by $1^* + 0.2 \times 1 + 0.8 \times 2$. R.N.A. model, HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system; HCV, hepatitis C virus. $^*Return$ after being informed of an anti-HCV+ status, with further HCV RNA testing required. $^+Return$ after being informed of an anti-HCV– status in the 20% of spontaneous seroconverters, with no further testing needed. $^†Return$ after being informed of an HCV RNA– status in the 80% of viremic patients, with further HCV genotyping and one more visit required for the final report.
R.N.A. strategy were enrolled for comparison between January 2019 and November 2019.

Patients were excluded if they had a history of receiving antiviral therapy, which was clarified by an electronic medical chart review.

DAA treatment

The National Health Insurance Administration of Taiwan began to reimburse DAA in January 2017, and there are currently no limitations for treating CHC patients with DAA. The treatment regimens and strategies conformed to the regional consensus and regulations of the Health and Welfare Department of Taiwan. The treatment regimens in the current study included sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, elbasvir/grazoprevir, and glecaprevir/pibrentasvir. HCV antibodies were detected by a third-generation enzyme immunoassay (Abbott Laboratories, North Chicago, IL, USA). HCV RNA and the genotypes were determined using a real-time PCR assay (RealTime HCV; Abbott Molecular, Des Plaines IL, USA; detection limit: 12 IU/mL). The institutional review board of Kaohsiung Medical University Hospital approved the protocols, which followed the guidelines of the International Conference on Harmonization for Good Clinical Practice (IRB approval numbers: KMUHIRB-F(I)-20170053, KMUHIRB-E(I)-20200245).

Statistical analyses

Frequencies were compared between groups using the chi-squared test with the Yates correction or Fisher’s exact test. Group means (presented as the mean±standard deviation) were compared using analysis of variance and Student’s t-test or the nonparametric Mann-Whitney test when appropriate. The HCV RNA diagnostic rate and treatment rate were compared between hepatology and non-hepatology departments. All other sections or departments apart from Division of Hepatobiliary Medicine in Kaohsiung Medical University Hospital were categorized as non-hepatology departments. The HCV treatment uptake is defined as the proportion of known viremic patients being treated among all anti-HCV seropositive patients (HCV RNA diagnostic rate multiplied by treatment rate). The statistical analyses were performed using the SPSS ver. 12.0 statistical package (SPSS, Chicago, IL, USA). All statistical analyses were based on two-sided hypothesis tests with a significance level of P<0.05.

RESULTS

After excluding 82 patients with a prior history of antiviral treat-

Table 1. Characteristics of anti-HCV seropositive patients with or without HCV intervention

|                      | R.N.A model (-) (n=1,396) | R.N.A model (+) (n=125) | P-value |
|----------------------|---------------------------|-------------------------|---------|
| Male gender          | 675 (48.4)                | 74 (59.2)               | 0.02    |
| Age (years)          | 58.9±13.3                 | 58.6±14.8               | 0.27    |
| Patient source       |                           |                         |         |
| Hepatology department| 1,139 (81.6)              | 68 (54.4)               | <0.001  |
| Non-hepatology depart-|ment*                     | 257 (18.4)              | 57 (45.6)|
| Diabetes             | 233 (16.7)                | 22 (17.6)               | 0.79    |
| Hypertension         | 469 (33.6)                | 50 (40.0)               | 0.15    |
| Cardiovascular disease| 44 (3.2)                 | 6 (4.8)                 | 0.30    |
| Cerebrovascular disease| 80 (5.7)                 | 8 (6.4)                 | 0.76    |
| White blood cell (×1,000/mm<sup>3</sup>) | 5,969±1,931 | 6,199±2,228 | 0.41    |
| Hemoglobin (g/dL)    | 15.8±1.8                  | 13.5±1.9                | 0.32    |
| Platelet count       | 203±70                    | 198±77                  | 0.60    |
| AST (IU/L)           | 57.0±44.9                 | 61.4±41.8               | 0.41    |
| ALT (IU/L)           | 66.6±70.6                 | 74±63.9                 | 0.34    |
| Creatinine (mg/dL)   | 1.27±1.79                 | 1.14±1.22               | 0.41    |
| HCV RNA† (log IU/mL) | 5.69±1.13                 | 5.48±1.23               | 0.18    |
| HCV genotype 1†, n/N (%) | 493/948 (52.0) | 54/100 (54.0) | 0.70    |
| DAA regimen‡         |                           | <0.001                  |         |
| EBR/GZR              | 156 (17.2)                | 1 (1.2)                 |         |
| SOF/LDV              | 311 (34.2)                | 0 (0.0)                 |         |
| GLE/PIB              | 304 (33.5)                | 32 (38.6)               |         |
| SOF/VEL              | 137 (15.1)                | 50 (60.2)               |         |

Values are presented as mean±standard deviation or number (%) unless otherwise indicated.

HCV, hepatitis C virus; R.N.A. model, HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DAA, direct-acting antiviral; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; LDV, ledipasvir; GLE, glecaprevir; PIB, pibrentasvir; VEL, velpatasvir.‡ Including Division of Infectious Diseases (n=54), Department of Otolaryngology (n=53), Department of Psychiatry (n=49), Department of Surgery (n=43), Division of Nephrology (n=31), Division of Endodontics and Operative Dentistry (n=18), Division of Pulmonary Medicine (n=15), Department of Family Medicine (n=13), and others (n=38).† Among patients with data available.

991 patients received DAA treatment.
ment, one hundred and twenty-five patients who adopted the R.N.A. model were recruited up to April 2020. Another 1,396 controls who did not adopt the R.N.A. model were enrolled for comparison. Compared to patients without the intervention, the group that was treated according to the R.N.A. model had a higher proportion of males (59.2% vs. 48.4%, P=0.02). The proportion of patients from non-hepatology departments significantly increased after the implementation of the model (45.6% vs. 18.4%, P<0.001). A higher proportion of patients who received sofosbuvir/velpatasvir was noted in the R.N.A. model group. Other patient characteristics were similar between the two patient cohorts (Table 1). The most common patient source from non-hepatology departments was the Division of Infectious Diseases (n=54), followed by the Department of Otolaryngology (n=53), Department of Psychiatry (n=49), Department of Surgery (n=43), Division of Nephrology (n=31), Division of Endodontics and Operative Dentistry (n=18), Division of Pulmonary Medicine (n=15), Department of Family Medicine (n=13), and others (n=38).

Among anti-HCV seropositive subjects, the HCV RNA testing rate was significantly higher in patients who received reflex testing than in those without reflex testing (100% [125/125] vs. 84.8% [1,184/1,396], P<0.001). Of the patients who received HCV RNA testing, the viremia rate was 80.1% (948/1,184) in the nonreflex testing group and 80.0% (100/125) in the reflex testing group. Among the viremic subjects, the rate of HCV genotyping was similar between patients with or without reflex testing (100% [100/100] vs. 98.9% [938/948], P=0.61). When the patients were stratified according to the referring outpatient department, a significant improvement in the diagnostic rate by RNA reflex testing was particularly noted for patients from non-hepatology departments (100% vs. 23.3%, P<0.001) but not for those from hepatology department (100% vs. 98.7%, P=0.999) (Table 2).

The treatment rate in HCV RNA seropositive patients was 83% (83/100) after the adoption of the R.N.A. model. After excluding two patients who passed away due to liver failure and one patient who decided to receive treatment in a nearby hospital, patients from the hepatology department had a significantly higher treatment rate than those from non-hepatology departments (96.1% vs. 73.9%, P=0.002). Of the 12 patients from non-hepatology departments who did not receive antiviral therapy, eight patients decided to postpone treatment due to fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during hospital visits, three other patients refused treatment due to personal reasons despite being well informed, and the other patient lost contact. The modified treatment rate was 89.5% (34/38) after excluding the eight patients who chose to postpone treatment.

### Table 2. Comparison of the diagnostic rate and treatment rate of anti-HCV seropositive patients with or without intervention

|                              | R.N.A. model (-) | R.N.A. model (+) | P-value |
|------------------------------|------------------|------------------|---------|
| RNA testing in anti-HCV+ patients | 84.8% (1,184/1,396) | 100.0% (125/125) | <0.001  |
| Hepatology department        | 98.7% (1,124/1,139)* | 100.0% (68/68) | 0.999   |
| Non-hepatology department     | 23.3% (60/257)*   | 100.0% (57/57) | <0.001  |
| HCV genotyping in HCV RNA+ patients | 98.9% (938/948) | 100.0% (100/100) | 0.61    |
| Hepatology department        | 99.1% (922/930)  | 100.0% (54/54) | 0.999   |
| Non-hepatology department     | 88.9% (16/18)    | 100.0% (46/46) | 0.08    |
| Treatment rate in HCV RNA+ patients | 95.8% (908/948) | 83% (83/100) | <0.001  |
| Hepatology department        | 97.1% (903/930)* | 96.1% (49/51)* | 0.66    |
| Non-hepatology department     | 27.8% (5/18)*    | 73.9% (34/46) | 0.001   |
| HCV treatment uptake*         | 81.2%            | 83.0%            | 0.85    |
| Hepatology department        | 95.8%            | 96.1%            | 0.76    |
| Non-hepatology department     | 6.4%             | 73.9%            | <0.001  |

HCV, hepatitis C virus; R.N.A. model, HCV Reflex testing; Call-back by Nursing coordinators; Automatic appointment system.

*P<0.001.† P=0.002.

Excluding two patients with mortality due to liver failure and one patient who decided to be treated in the nearby hospital. The two untreated patients had active hepatocellular carcinoma.

Excluding two patients with mortality due to liver failure and one patient who decided to be treated in the nearby hospital. The two untreated patients had active hepatocellular carcinoma.

HCV treatment uptake denoted as the proportion of known viremic patients being treated among anti-HCV seropositive patients (HCV RNA diagnostic rate × treatment rate).
Compared to subjects who did not adopt the R.N.A. model, a significant improvement in the treatment rate was observed for patients from non-hepatology departments (73.9% vs. 27.8%, \( P=0.001 \)) but not for those from hepatology departments (96.1% vs. 97.1%, \( P=0.66 \)) (Table 2).

Overall, the HCV treatment uptake of known viremic patients among the anti-HCV seropositive patients was similar between patients treated with or without the implementation of R.N.A. model (81.2% vs. 83%, \( P=0.85 \)). The treatment uptake rate did not differ for the patients from hepatology department (95.8% vs. 96.1%, \( P=0.76 \)). Instead, the application of the R.N.A. model significantly increased the in-hospital HCV treatment uptake rate from 6.4% to 73.9% for patients from non-hepatology departments (\( P<0.001 \)) (Table 2).

**DISCUSSION**

The current study demonstrated that the implementation of HCV reflex testing significantly improved the HCV diagnostic rate. Following an in-hospital automatic transferal system and late callback modality further promoted disease awareness and treatment accessibility. The sequential care cascade particularly worked on patients who originally visited the hospital for reasons other than the treatment of hepatitis. Before adopting the R.N.A. strategy, only one-quarter of the anti-HCV seropositive patients from the non-hepatology departments received HCV RNA testing. Furthermore, only one-quarter of the viremic patients received DAAs, which in turn led to very poor HCV treatment uptake. After launching the strategy, the proportion of patients who came from the non-hepatology departments significantly increased. In addition, a 4-fold improvement in the HCV RNA diagnostic rate after the HCV reflex test and a nearly 3-fold improvement in the treatment rate after automatic transfer was observed, showing drastically scaled up treatment by the in-hospital care cascade. As a result, the huge gap between accurate diagnosis and final treatment was overcome, particularly for patients who originally visited non-hepatology departments.

The accurate and timely diagnosis of HCV infection may pave the way for improved HCV care and is key to facilitating the HCV care cascade. It has been reported that one-third of anti-HCV seropositive patients do not receive HCV RNA testing in developed regions, and the major reason for failing to perform the confirmation test was that the patient did not return for follow-up.\(^{17} \) Interrupted time series analysis revealed that the implementation of HCV reflex testing had the largest impact on the ability to complete timely HCV RNA testing.\(^{17} \) Currently, HCV reflex testing has rarely been adopted in Taiwan. Nevertheless, it has been reported that the implementation rate of HCV reflex testing has increased from 31% to 89% among large teaching hospitals in Spain from 2017 to 2019.\(^{12} \) The applicability of HCV reflex testing by repeatedly using the same blood sample is based on the high accuracy and degree of correlation compared to those achieved with the use of fresh blood samples.\(^{18} \) HCV reflex testing is time saving, and it also reduces the cost of transportation and outpatient visit fees before patients from either hepatology or non-hepatology departments receive a confirmation of their infection status. Assuming that the HCV viremia rate is 80% and the HCV spontaneous clearance rate is 20% in anti-HCV seropositive patients, an average of 2.8 visits was needed for patients without reflex testing before they could be allocated to antiviral treatment, while only one visit was needed for patients with reflex testing. The strategy of the RNA model could also be applied to populations at-risk for HCV, such as residents in HCV hyperendemic areas,\(^{1,3} \) prisoners,\(^{19} \) intravenous drug users,\(^{20} \) and patients with uremia under maintenance hemodialysis\(^{21,22} \) to facilitate HCV microelimination.

Due to the pandemic caused by the SARS-CoV-2 infection, fewer patients have visited the hospital during the past few months after we implemented the R.N.A. strategy. Taiwan successfully controlled the pandemic, and fewer than 450 subjects has been infected with the virus that causes coronavirus disease 2019 (COVID-19) as of June 2020.\(^{24} \) Regional guidance has suggested that routine treatment of HCV may not be warranted based on the burden of COVID-19 and local official implementations and regulations.\(^{25,26} \) It is reasonable that the treatment rate of patients from non-hepatology departments was reduced due to fears of contracting COVID-19. All of these patients originally visited the hospital for reasons other than HCV treatment. Due to the adequate control of the SARS-CoV-2 infection, we took positive action in managing these HCV patients. Because of good compensation, which led to a 100% HCV RNA diagnostic rate, and an aggressive referral strategy, the overall HCV treatment uptake was similar among patients before and after R.N.A. model implementation, even though we faced the critical situation of COVID-19. Notably, nearly half of the patients were referred from non-hepatology departments, and the treatment uptake of those patients was significantly increased, indicating the success of the model in facilitating in-hospital HCV elimination. In conclusion, the implementation of HCV reflex testing followed by active trans-
fer significantly increased HCV treatment uptake. The integration of these strategies allowed for timely and accurate diagnosis by raising disease awareness and facilitating access to liver clinics, which closed the gap between the confirmation of HCV infection and final treatment allocation. This continuous in-hospital care cascade may serve as an exemplar for other primary care systems.

Authors' contribution
Conception and design: Ming-Lung Yu

Acquisition of data: Ming-Lun Yeh, Pey-Fang Wu, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Zu-Yau Lin, Shinn-Chereng Chen, Hung-Yin Liu, Ying-Chou Huang, Jee-Fu Huang, Chia-Yen Dai, and Wan-Long Chuang

Data analysis and interpretation: Chung-Feng Huang and Ming-Lung Yu

Manuscript drafting and critical revision: Chung-Feng Huang and Ming-Lung Yu

Approval of the final version of the manuscript: Ming-Lung Yu

Acknowledgements
The study was supported by grants from Kaohsiung Medical University (MOST 108-2314-B-037-001-MY3, [Center for Cancer Research KMU-TC108A04-3]), [Center for Liquid Biopsy KMU-TC108B06] and [Cohort Research Center KMU-TC108B07, KMU-DK109002]) and Kaohsiung Medical University Hospital (KMUH108-BR09, KMU-DK(世)109002, KMU-DK(整)109005~1, KMUH108-BR05).

Conflicts of Interest
The authors have no conflicts to disclose.

REFERENCES
1. World Health Organization (WHO). Hepatitis C. WHO web site, <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Accessed 19 Jun 2020.
2. Yu ML, Yeh ML, Tsai PC, Huang CI, Huang JF, Huang CF, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) 2015;94:e690.
3. Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010;26:461-469.
4. Chen YY, Chen CL, Chen JW, Hsu NT, Wei ST, Hou SM, et al. Secular trends and geographic maps of hepatitis C virus infection among 4 million blood donors in Taiwan from 1999 to 2017. Hepatol Commun 2020;4:1193-1205.
5. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. WHO web site, <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1>. Accessed 7 Dec 2020.
6. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C consortium. Hepatol Int 2019;13:587-598.
7. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, et al. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open 2019;9:e026703.
8. Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol 2020;26:251-260.
9. Turner BJ, Rochat A, Lill S, Bobadilla R, Hernandez L, Choi A, et al. Hepatitis C virus screening and care: complexity of implementation in primary care practices serving disadvantaged populations. Ann Intern Med 2019;171:865-874.
10. McGibbon E, Bornschlegel K, Balter S. Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients. Am J Med 2013;126:718-722.
11. Chevaliez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti Infect Ther 2019;17:341-347.
12. Crespo I, Lázaro P, Blasco AJ, Aguiler A, García-Samaniego J, Eiros JM, et al. Hepatitis C reflex testing in Spain in 2019: a story of success. Enferm Infecc Microbiol Clin. 2020 May 22. doi: 10.1016/j.eimc.2020.03.004.
13. Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc 2020;119:1019-1040.
14. Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (II) special populations. J Formos Med Assoc 2020;119:1135-1157.
15. National Health Insurance Administration. Ministry of Health and Welfare. National Health Insurance Administration web site, <https://www.nhi.gov.tw/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D0959025979>. Accessed 19 Jun 2020.
16. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011;52:133-137.
17. Hirsch AA, Lawrence RH, Kern E, Falck-Ytter Y, Shumaker DT, Watts B. Implementation and evaluation of a multicomponent quality im-
provement intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J Qual Patient Saf 2014;40:351-357.
18. Gale HB, Dufour DR, Qazi NN, Kan VL. Comparison of serial hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation. J Clin Microbiol 2011;49:3036-3039.
19. Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF, et al. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PLoS One 2014;9:e94791.
20. Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, et al. Integrated care for methadone maintenance patients with hepatitis C virus infection. Kaohsiung J Med Sci 2019;35:501-507.
21. Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol 2014;60:253-259.
22. Huang CF, Yeh ML, Lee JJ, Chen MC, Dai CY, Huang JF, et al. Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. Hepatol Int 2014;8:224-232.
23. Huang CF, Chiu YW, Yu ML. Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients. Kidney Int 2020;97:421.
24. Taiwan Centers for Disease Control. COVID-19 (SARS-CoV-2 Infection) case number update. Taiwan Centers for Disease Control website, <https://sites.google.com/cdc.gov.tw/2019ncov/taiwan>. Accessed 20 Jun 2020.
25. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 2020;72:287-304.
26. Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol 2020;5:776-787.